March 2023: Ososayensi abenze umuthi omusha ongase uphumelele kuzo zonke izinhlobo eziyinhloko zomdlavuza wamathambo ezinganeni baye bawubiza ngokuthi “isidakamizwa esibaluleke kakhulu esitholwe emkhakheni cishe phakathi nengxenye yekhulu leminyaka.”
Ukuhlolwa kwamagundane afakwe nomdlavuza wamathambo omuntu kubonise amandla e-CADD522 okuvimbela isakhi sofuzo esixhumene nekhono lokusabalala komdlavuza.
The findings, which were published in the Journal of Bone Oncology, demonstrated, according to the researchers, that the drug can increase survival rates by 50% without the need for surgery or chemotherapy.
Lead researcher Dr Darrell Green, from the University of East Anglia’s Norwich Medical School, said: “Primary umdlavuza wamathambo is a type of cancer that begins in the bones.
Lokhu kuphumelela kubaluleke kakhulu ngoba ukwelashwa komdlavuza wamathambo akukashintshi iminyaka engaphezu kwengu-45.
UDkt Darrell Green
“Umdlavuza wezingane oqinile ojwayelekile endaweni yesithathu, ngemuva kobuchopho nezinso, cishe unabantu abasha abangu-52,000 minyaka yonke emhlabeni jikelele.
“Ingasakazeka ngokushesha kwezinye izingxenye zomzimba, futhi lesi yisici esiyinkinga kakhulu yalolu hlobo lomdlavuza.
“Uma umdlavuza ususabalele, kuba nzima kakhulu ukwelapha ngenhloso yokwelapha.”
Njengamanje, ukwelashwa ngamakhemikhali nokunqunywa kwesitho yikona kuphela ukwelashwa komdlavuza wamathambo, okunethuba elingu-42% lokusinda.
Ngokwabacwaningi, “isidakamizwa sabo esiphumelelayo” sandisa amazinga okusinda ngamaphesenti angu-50 futhi asinayo imiphumela emibi yokwelapha ngamakhemikhali, njengokuqothuka kwezinwele, ukukhathala nokugula.
Abacwaningi bahlaziye amasampula esimila samathambo ezigulini eziyi-19 esibhedlela iRoyal Orthopedic Hospital eBirmingham ngenhloso yocwaningo.
Bathole ukuthi isakhi sofuzo i-RUNX2 sisebenza kumdlavuza wethambo oyinhloko futhi sihlotshaniswa nokusabalala kwalesi sifo.
Ngokokuhlolwa, i-CADD522 ivimbela iphrotheni ye-RUNX2 ekukhuthazeni ukukhula komdlavuza.
UDkt. Green uthe, “Ukusinda okungenama-metastasis kukhuphuke ngo-50% ezivivinyweni zangaphambi komtholampilo lapho umuthi omusha we-CADD522 usetshenziswa wodwa, ngaphandle kokwelashwa ngamakhemikhali noma ukuhlinzwa.
“Nginethemba lokuthi uma kuhlangene nezinye izindlela zokwelapha ezifana nokuhlinzwa, lesi sibalo sokusinda sizokwenyuka.
“Okubalulekile, ngenxa yokuthi ufuzo lwe-RUNX2 aluvamisile ukudingwa amaseli avamile, umuthi awubangeli imiphumela engemihle njenge-chemotherapy.
Njengoba ukwelashwa komdlavuza wamathambo kungashintshile eminyakeni engaphezu kwengu-45, lokhu kutholakala kubaluleke kakhulu.
According to the researchers, the drug is currently undergoing toxicology testing, after which the team will seek approval from the MHRA (Medicines and Healthcare products Regulatory Agency) to begin a isivivinyo somtholampilo on humans.
Ososayensi abavela eNyuvesi yaseSheffield, eNyuvesi yaseNewcastle, iRoyal Orthopedic Hospital yaseBirmingham, kanye neNorfolk and Norwich Hospital nabo babambe iqhaza ocwaningweni, olwasekelwa uSir William Coxen Trust kanye noBig C.
UDkt. Green uthe ukushona komngane wakhe omkhulu ngenxa yomdlavuza wamathambo ebuntwaneni kwamkhuthaza ukuba afunde ngalesi sifo.
“Bengifuna ukuqonda umsuka webhayoloji yokusabalala komdlavuza ukuze sikwazi ukungenelela ezingeni lasemtholampilo futhi sithuthukise izindlela zokwelapha ezintsha ukuze iziguli zingadluleli kulokho umngane wami uBen,” echaza.
